UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 8 von 277
Datensatz exportieren als...
BibTeX
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
Cancer, 2018-03, Vol.124 (6), p.1111-1121
Barroso‐Sousa, Romualdo
Ott, Patrick A.
Hodi, F. Stephen
Kaiser, Ursula B.
Tolaney, Sara M.
Min, Le
2018
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Barroso‐Sousa, Romualdo
Ott, Patrick A.
Hodi, F. Stephen
Kaiser, Ursula B.
Tolaney, Sara M.
Min, Le
Titel
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
Ist Teil von
Cancer, 2018-03, Vol.124 (6), p.1111-1121
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2018
Quelle
MEDLINE
Beschreibungen/Notizen
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. However, because ICIs block coinhibitory molecules on T cells and other immune cells, unleashing them to mediate tumor cell killing, they also can disrupt the maintenance of immunological tolerance to self‐antigens. Compared with chemotherapy, ICIs have a different toxicity profile, especially the occurrence of autoimmune‐like manifestations against multiple organ systems, including endocrine glands, commonly referred to as immune‐related adverse events. The aim of this review was to provide practical recommendations regarding the proper assessment and clinical management related to the new onset of endocrinopathies after the use of ICIs in patients with cancer. Cancer 2018;124:1111‐21. © 2018 American Cancer Society. The risk of endocrine dysfunction resulting from immune checkpoint blockade differs among different immune checkpoint inhibitor (ICI) regimens, and is higher with combination therapy. Early recognition of endocrine dysfunction resulting from ICI use is important to prevent life‐threatening complications. Herein, the authors review practical recommendations regarding the proper assessment and clinical management related to the new onset of endocrinopathies after the use of ICIs in patients with cancer.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.31200
Titel-ID: cdi_proquest_journals_2010862321
Format
–
Schlagworte
adrenal insufficiency
,
Antigens
,
Antineoplastic Agents, Immunological - administration & dosage
,
Antineoplastic Agents, Immunological - adverse effects
,
Autoantigens
,
autoimmune diabetes
,
Autoimmunity - drug effects
,
Cancer
,
Chemotherapy
,
Costimulatory and Inhibitory T-Cell Receptors - antagonists & inhibitors
,
Costimulatory and Inhibitory T-Cell Receptors - immunology
,
Endocrine disorders
,
Endocrine glands
,
Endocrine Glands - drug effects
,
Endocrine Glands - immunology
,
Endocrine System Diseases - chemically induced
,
Endocrine System Diseases - diagnosis
,
Endocrine System Diseases - therapy
,
Humans
,
hyperthyroidism
,
hypophysitis
,
hypothyroidism
,
Immune checkpoint inhibitors
,
Immune system
,
immune‐related adverse events
,
Immunological tolerance
,
Immunology
,
Inhibitors
,
Lymphocytes
,
Lymphocytes T
,
Medical diagnosis
,
Neoplasms - drug therapy
,
Neoplasms - immunology
,
Oncology
,
Practice Guidelines as Topic
,
thyroiditis
,
Toxicity
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX